Daratumumab for the Treatment of Patients With AL Amyloidosis

NCT02841033 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

AL Amyloidosis

Interventions

DRUG: daratumumab

Sponsor

Boston Medical Center

Collaborators

[object Object]